EBC-46. scientists find a cure for tumors and cancer in dogs.
taken from EcoBiotics Clinical Trials
EBC-46 is a new experimental drug for treating cancers in dogs, cats and horses
Australian drug discovery company EcoBiotics Ltd is developing a new drug, EBC-46, for the local treatment of a wide range of cancers in dogs, cats and horses.
In trials with a small number of dogs, cats and horses, intralesional injection of EBC-46 has successfully ablated or significantly palliated a range of advanced, inoperable tumours (melanomas, sarcomas, carcinomas, mast cell tumours & sarcoids) while causing no significant long-term side effects. A topical formulation of EBC-46 has also been used to successfully treat ulcerative squamous cell carcinomas on cats and horses.
EBC-46 is delivered locally in a single treatment by direct injection into tumours, or by topical application onto the tumour surface, and works principally by stimulating the patient’s innate immune system to destroy the tumour.
EBC-46 is active against a wide range of tumour types and is potentially useful in treating any tumour that can be accessed for direct injection or topical application of the drug.
EBC-46 only works locally at the site of delivery and there is no current evidence to suggest that EBC-46 has any systemic efficacy against metastatic disease in affecting remote secondary tumours.
taken from EcoBiotics Clinical Trials
EBC-46 is a new experimental drug for treating cancers in dogs, cats and horses
Australian drug discovery company EcoBiotics Ltd is developing a new drug, EBC-46, for the local treatment of a wide range of cancers in dogs, cats and horses.
In trials with a small number of dogs, cats and horses, intralesional injection of EBC-46 has successfully ablated or significantly palliated a range of advanced, inoperable tumours (melanomas, sarcomas, carcinomas, mast cell tumours & sarcoids) while causing no significant long-term side effects. A topical formulation of EBC-46 has also been used to successfully treat ulcerative squamous cell carcinomas on cats and horses.
EBC-46 is delivered locally in a single treatment by direct injection into tumours, or by topical application onto the tumour surface, and works principally by stimulating the patient’s innate immune system to destroy the tumour.
EBC-46 is active against a wide range of tumour types and is potentially useful in treating any tumour that can be accessed for direct injection or topical application of the drug.
EBC-46 only works locally at the site of delivery and there is no current evidence to suggest that EBC-46 has any systemic efficacy against metastatic disease in affecting remote secondary tumours.

Please Scroll Down to See Forums Below 










